Format

Send to

Choose Destination
BMC Med Genomics. 2016 Jan 5;9:1. doi: 10.1186/s12920-015-0162-5.

The IGNITE network: a model for genomic medicine implementation and research.

Author information

1
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida (UF) College of Pharmacy, Gainesville, FL, USA. kweitzel@cop.ufl.edu.
2
Center for Therapeutic Effectiveness Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mmga@mail.med.upenn.edu.
3
Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Barbara.Bernhardt@uphs.upenn.edu.
4
Institute for Family Health, New York, NY, USA. neil.calman@mssm.edu.
5
Weis Center for Research, Geisinger Health System, Danville, PA, USA. djcarey@geisinger.edu.
6
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida (UF) College of Pharmacy, Gainesville, FL, USA. lcavallari@cop.ufl.edu.
7
Institute for Clinical and Translational Research, School of Medicine, Vanderbilt University, Nashville, TN, USA. julie.r.field@Vanderbilt.Edu.
8
Institute for Family Health, New York, NY, USA. diane.l.hauser@mssm.edu.
9
Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. junkinsh@mail.nih.gov.
10
Bay West Endocrinology Associates and MODEL Clinical Research, Baltimore, MD, USA. pal3420@YAHOO.COM.
11
Department of Medicine, Indiana University School of Medicine, Indiana, IN, USA. kdlevy@iu.edu.
12
Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. maddeneb@mail.nih.gov.
13
Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. manoliot@mail.nih.gov.
14
Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. jacqueline.odgis@nih.gov.
15
Division of General Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA. lori.orlando@DUKE.EDU.
16
Duke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, 101 Science Dr, Rm 2111, CIEMAS Bldg, Durham, NC, 27708, USA. lori.orlando@DUKE.EDU.
17
Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. reed.pyeritz@UPHS.UPENN.EDU.
18
Division of General Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA. ryanne.wu@duke.edu.
19
Duke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, 101 Science Dr, Rm 2111, CIEMAS Bldg, Durham, NC, 27708, USA. ryanne.wu@duke.edu.
20
University of Maryland School of Medicine, Baltimore, MD, USA. ASHULDIN@medicine.umaryland.edu.
21
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. ASHULDIN@medicine.umaryland.edu.
22
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. erwin.bottinger@mssm.edu.
23
Departments of Biomedical Informatics and Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. josh.denny@vanderbilt.edu.
24
Division of General Internal Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. josh.denny@vanderbilt.edu.
25
Department of Medicine, Indiana University School of Medicine, Indiana, IN, USA. prdexter@IUPUI.EDU.
26
Department of Medicine, Indiana University School of Medicine, Indiana, IN, USA. dflockha@IU.EDU.
27
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Carol.Horowitz@MOUNTSINAI.ORG.
28
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida (UF) College of Pharmacy, Gainesville, FL, USA. Julie.johnson@ufl.edu.
29
Center for Therapeutic Effectiveness Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. stevek@MAIL.MED.UPENN.EDU.
30
Center for Clinical Epidemiology and Biostatistics, Center for Therapeutic Effectiveness Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. stevek@MAIL.MED.UPENN.EDU.
31
Departments of Biomedical Informatics and Medicine, Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA. mia.levy@VANDERBILT.EDU.
32
University of Maryland School of Medicine, Baltimore, MD, USA. tpollin@MEDICINE.UMARYLAND.EDU.
33
Duke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, 101 Science Dr, Rm 2111, CIEMAS Bldg, Durham, NC, 27708, USA. geoffrey.ginsburg@DM.DUKE.EDU.

Abstract

BACKGROUND:

Patients, clinicians, researchers and payers are seeking to understand the value of using genomic information (as reflected by genotyping, sequencing, family history or other data) to inform clinical decision-making. However, challenges exist to widespread clinical implementation of genomic medicine, a prerequisite for developing evidence of its real-world utility.

METHODS:

To address these challenges, the National Institutes of Health-funded IGNITE (Implementing GeNomics In pracTicE; www.ignite-genomics.org ) Network, comprised of six projects and a coordinating center, was established in 2013 to support the development, investigation and dissemination of genomic medicine practice models that seamlessly integrate genomic data into the electronic health record and that deploy tools for point of care decision making. IGNITE site projects are aligned in their purpose of testing these models, but individual projects vary in scope and design, including exploring genetic markers for disease risk prediction and prevention, developing tools for using family history data, incorporating pharmacogenomic data into clinical care, refining disease diagnosis using sequence-based mutation discovery, and creating novel educational approaches.

RESULTS:

This paper describes the IGNITE Network and member projects, including network structure, collaborative initiatives, clinical decision support strategies, methods for return of genomic test results, and educational initiatives for patients and providers. Clinical and outcomes data from individual sites and network-wide projects are anticipated to begin being published over the next few years.

CONCLUSIONS:

The IGNITE Network is an innovative series of projects and pilot demonstrations aiming to enhance translation of validated actionable genomic information into clinical settings and develop and use measures of outcome in response to genome-based clinical interventions using a pragmatic framework to provide early data and proofs of concept on the utility of these interventions. Through these efforts and collaboration with other stakeholders, IGNITE is poised to have a significant impact on the acceleration of genomic information into medical practice.

PMID:
26729011
PMCID:
PMC4700677
DOI:
10.1186/s12920-015-0162-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center